Skip to main content
Premium Trial:

Request an Annual Quote

ABI to Use Berry & Associates' Reagent with SOLiD Sequencer

NEW YORK (GenomeWeb News) – The biochemistry specialty company Berry & Associates said today that it will supply Applied Biosystems with a custom reagent for use with its SOLiD second-generation sequencer.
Under the five-year agreement, Berry & Associates said it will supply ABI with a custom nucleoside phosphoramidite that “meets the high purity standards required for synthesis of the oligonucleotide probes that are used in the SOLiD System.”
Berry & Associates is a private company based in Dexter, Mich., that offers custom nucleosides, nucleotides, monomers for DNA and RNA synthesis, fluorescent markers, and other biochemical agents.
Financial terms of the agreement were not released.

The Scan

Panel Votes for COVID-19 Pill

A US Food and Drug Administration panel has voted to support the emergency use authorization of an antiviral pill for COVID-19 from Merck and Ridgeback Biotherapeutics, CNN says.

But Not Harm

New Scientist reports that UK bioethicists say that though gene editing may improve food production, it should not harm livestock welfare.

Effectiveness Drop Anticipated

Moderna's Stéphane Bancel predicts that that current SARS-CoV-2 vaccines may be less effective against the Omicron variant, the Financial Times reports.

Cell Studies of Human Chromatin Accessibility, SARS-CoV-2 Variants, Cell Signaling Networks

In Cell this week: chromatin accessibility maps of adult human tissues, modeling to track SARS-CoV-2 variants of concern, and more.